SLPI and triple-negative breast carcinoma: Among these, SLPI (Secretory Leukocyte Protease Inhibitor) is involved in inflammation inhibition, immune response modulation, and cell proliferation promotion31, and is found to be elevated in triple-negative breast cancer patients with poor prognosis32.